Comparative Pharmacology
Head-to-head clinical analysis: ENDURON versus HYDROPANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURON versus HYDROPANE.
ENDURON vs HYDROPANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
Thiazide diuretic; inhibits sodium chloride cotransporter in distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Oral, 2.5–5 mg once daily. Maximum dose 10 mg/day.
50–100 mg orally once daily, maximum 200 mg daily
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (mean 36 hours); prolonged in renal impairment or heart failure, allowing once-daily dosing.
Terminal elimination half-life is approximately 8-15 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal (15-30%); dose adjustment required in renal impairment (CrCl <30 mL/min).
Renal (approximately 50% as unchanged drug) and hepatic metabolism to inactive metabolites; fecal elimination accounts for about 10%.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic